Search results
Showing 1 to 15 of 104 results for kidney cancer
This quality standard covers diagnosing and managing renal cell carcinoma in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS215Show all sections
Sections for QS215
- Quality statements
- Quality statement 1: Suspected cancer pathway referral
- Quality statement 2: Renal biopsy for small renal lesions
- Quality statement 3: Clinical nurse specialist
- Quality statement 4: Surgery with curative intent
- Quality statement 5: Follow-up imaging
- Quality statement 6: Uro–oncology multidisciplinary team
- About this quality standard
This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.
Show all sections
Sections for NG256
- Overview
- Information and support
- Diagnosis
- Managing oncocytomas and Bosniak 2F cysts
- Managing localised and locally advanced renal cell carcinoma
- Managing advanced renal cell carcinoma
- Managing renal cell carcinoma in people with a heritable renal cell carcinoma predisposition syndrome
- Terms used in this guideline
In development Reference number: GID-TA11186 Expected publication date: TBC
Urinary incontinence in neurological disease: assessment and management (CG148)
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Laparoscopic nephrectomy (including nephroureterectomy) (HTG84)
Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy). This involves making small incisions (keyhole surgery) to remove the damaged kidney, or kidney, ureter and surrounding tissue.
View recommendations for HTG84Show all sections
Sections for HTG84
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS76Show all sections
Sections for QS76
- Quality statements
- Quality statement 1: Raising awareness in people at risk
- Quality statement 2: Identifying acute kidney injury in people admitted to hospital
- Quality statement 3: Response to acute kidney injury warning stage 2 test result
- Quality statement 4: Response to acute kidney injury warning stage 3 test result
- Quality statement 5: Referral for renal replacement therapy
- Quality statement 6: Clinical review after hospital discharge
- Update information
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Neutropenic sepsis: prevention and management in people with cancer (CG151)
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.
Palliative care for adults: strong opioids for pain relief (CG140)
This guideline covers safe and effective prescribing of strong opioids for pain relief in adults with advanced and progressive disease. It aims to clarify the clinical pathway for prescribing and help to improve pain management and patient safety. Care during the last 2 to 3 days of life is covered by NICE's guideline on care of dying adults in the last days of life .
This quality standard covers diagnosing and managing urinary tract infections in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS90Show all sections
Sections for QS90
- Quality statements
- Quality statement 1: Diagnosing urinary tract infections in women under 65
- Quality statement 2: Diagnosing urinary tract infections in adults with catheters
- Quality statement 3: Antibiotic treatment for asymptomatic bacteriuria in men and non-pregnant women
- Quality statement 4: Duration of antibiotic treatment for urinary tract infection
- Quality statement 5: Referring adults with recurrent urinary tract infection
- Update information
- About this quality standard
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Evidence-based recommendations on imlifidase (Idefirix) for desensitisation treatment before kidney transplant in people with chronic kidney disease.
Irreversible electroporation for treating renal cancer (HTG303)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for HTG303Show all sections
Sections for HTG303
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.
View recommendations for HTG97Show all sections